Abstract: A user specifies a natural language command to a device. Software on the device generates contextual metadata about the user interface of the device, such as data about all visible elements of the user interface, and sends the contextual metadata along with the natural language command to a natural language understanding engine. The natural language understanding engine parses the natural language query using a stored grammar (e.g., a grammar provided by a maker of the device) and as a result of the parsing identifies information about the command (e.g., the user interface elements referenced by the command) and provides that information to the device. The device uses that provided information to respond to the command.

Abstract: A user specifies a natural language command to a device. Software on the device generates contextual metadata about the user interface of the device, such as data about all visible elements of the user interface, and sends the contextual metadata along with the natural language command to a natural language understanding engine. The natural language understanding engine parses the natural language query using a stored grammar (e.g., a grammar provided by a maker of the device) and as a result of the parsing identifies information about the command (e.g., the user interface elements referenced by the command) and provides that information to the device. The device uses that provided information to respond to the command.

Abstract: The present disclosure relates, inter alia, to cryptophycin conjugates of formula (V): The disclosure also relates to precursors of these conjugates, compositions containing these conjugates, and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Abstract: A user specifies a natural language command to a device. Software on the device generates contextual metadata about the user interface of the device, such as data about all visible elements of the user interface, and sends the contextual metadata along with the natural language command to a natural language understanding engine. The natural language understanding engine parses the natural language query using a stored grammar (e.g., a grammar provided by a maker of the device) and as a result of the parsing identifies information about the command (e.g., the user interface elements referenced by the command) and provides that information to the device. The device uses that provided information to respond to the command.

Abstract: A query-processing server provides natural language services to applications. More specifically, the query-processing server receives and stores domain knowledge information from application developers, the domain knowledge information comprising a linguistic description of the natural language user queries that application developers wish their applications to support. A first portion of the domain knowledge information is applied to transform a natural language query received from an application to an ordered sequence of question elements. A second portion of the domain knowledge information is applied to group the ordered sequence of question elements into a plurality of distinct structured questions posed by the natural language query. The distinct structured questions may then be provided to the application, which may then execute them and obtain the corresponding data referenced by the questions.

Abstract: The present disclosure relates to compounds of formula (I): RCG1-L-P??(I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Abstract: The present disclosure relates to compounds of formula (V): wherein Ab represents an antibody. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Abstract: The present disclosure relates to compounds of formula (I): RCG1-L-P (I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Abstract: The present disclosure relates to compounds of formula (I): RCG1-L-P??(I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Abstract: The present disclosure relates to compounds of formula (I): RCG1-L-P??(I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Abstract: Provided herein are compounds of formula (I):

Abstract: The invention relates to a method of analyzing spectral data for the selection of a calibration model, relating spectra of a substance to a physical or chemical parameter of the substance, over a predetermined range of the physical or chemical parameter, comprising the steps: a) capturing spectral data of the substance with respective values of the physical or chemical parameter over the predetermined range, b) creating a plurality of calibration models using the captured spectral data in dependence upon the values of the physical or chemical parameter based on the calibration data using statistical resampling methods, c) calculating tolerance intervals of the results at each reference level for each calibration model, and d) displaying the tolerance intervals at each reference level over the predetermined range for each calibration model.

Abstract: The invention relates to a method of analyzing spectral data for the selection of a calibration model, relating spectra of a substance to a physical or chemical parameter of the substance, over a predetermined range of the physical or chemical parameter, comprising the steps: a) capturing spectral data of the substance with respective values of the physical or chemical parameter over the predetermined range, b) creating a plurality of calibration models using the captured spectral data in dependence upon the values of the physical or chemical parameter based on the calibration data using statistical resampling methods, c) calculating tolerance intervals of the results at each reference level for each calibration model, and d) displaying the tolerance intervals at each reference level over the predetermined range for each calibration model.

Abstract: The invention relates to biotinylated low molecular weight heparins comprising constituent polysaccharides having at their reducing ends at least one covalent bond with biotin or a biotin derivative, and also to the process for preparing them, to pharmaceutical compositions containing them and to their therapeutic use.

Abstract: The invention relates to biotinylated heparins comprising constituent polysaccharides having at their reducing ends at least one covalent bond with biotin or a biotin derivative, and also to the process for preparing them, to pharmaceutical compositions containing them and to their therapeutic use. The biotinylated polysaccharides are of the formula (I) with the variables as defined herein.

Abstract: An improved tremolo mechanism for a guitar. The tremolo mechanism for a guitar includes a rotary assembly. The rotary assembly includes a main rotor that includes an arcuate shaped surface defining holes through which a plurality of guitar strings exit the main rotor when the tremolo mechanism is installed on a guitar, resilient means coupled to said main rotor to bias said rotary assembly to a first position at which no tremolo effect is provided and away from a second position at which a tremolo effect is provided and fixing means on the main rotor for securing one end of each of the plurality of guitar strings to the rotary assembly. The tremolo mechanism also includes a plurality of tension rollers for providing rotational tension to said guitar strings. Said arcuate shaped surface directionally guides said strings transverse of said rotary assembly to the tension rollers.

Abstract: An improved tremolo mechanism for a guitar. The tremolo mechanism for a guitar includes a rotary assembly. The rotary assembly includes a main rotor that includes an arcuate shaped surface defining holes through which a plurality of guitar strings exit the main rotor when the tremolo mechanism is installed on a guitar, resilient means coupled to said main rotor to bias said rotary assembly to a first position at which no tremolo effect is provided and away from a second position at which a tremolo effect is provided and fixing means on the main rotor for securing one end of each of the plurality of guitar strings to the rotary assembly. The tremolo mechanism also includes a plurality of tension rollers for providing rotational tension to said guitar strings. Said arcuate shaped surface directionally guides said strings transverse of said rotary assembly to the tension rollers.

Abstract: The present invention relates to the carboxyl-reduced derivatives of hyaluronic acid of formula (I): in which R or R1 represents H or SO3M, n is an integer of between 0 and 25 000, M is an alkali metal, isolated or as mixtures, to the diastereoisomers thereof, to the process for the preparation thereof, to the uses thereof as a medicinal product and to the pharmaceutical compositions containing them.

Abstract: The present invention relates to the carboxyl-reduced and chemoselectively O-sulfated derivatives of chondroitin sulfate of formula (I): in which R1, R2, R3 and R4 are H or SO3M, n is an integer of between 0 and 200, M is an alkali metal, isolated or as mixtures, to the diastereoisomers thereof, to the process for the preparation thereof, to the uses thereof as a medicinal product and to the pharmaceutical compositions containing them.

Abstract: The present invention relates to the carboxyl-reduced derivatives of dermatan sulfate of formula (I): in which R1, R2, R3 or R4 represents H or SO3M, n is an integer of between 0 and 150, M is an alkali metal, isolated or as mixtures, to the diastereoisomers thereof, to the process for the preparation thereof, to the uses thereof as a medicinal product and to the pharmaceutical compositions containing them.